MXPA05006359A - Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos. - Google Patents

Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos.

Info

Publication number
MXPA05006359A
MXPA05006359A MXPA05006359A MXPA05006359A MXPA05006359A MX PA05006359 A MXPA05006359 A MX PA05006359A MX PA05006359 A MXPA05006359 A MX PA05006359A MX PA05006359 A MXPA05006359 A MX PA05006359A MX PA05006359 A MXPA05006359 A MX PA05006359A
Authority
MX
Mexico
Prior art keywords
antimicrobial peptide
disease treatment
peptide inhibitors
treatment via
via antimicrobial
Prior art date
Application number
MXPA05006359A
Other languages
English (en)
Inventor
Yitzchak Hillman
Original Assignee
Yitzchak Hillman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL15355702A external-priority patent/IL153557A0/xx
Priority claimed from IL15698003A external-priority patent/IL156980A0/xx
Application filed by Yitzchak Hillman filed Critical Yitzchak Hillman
Publication of MXPA05006359A publication Critical patent/MXPA05006359A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Abstract

Se expone un metodo de tratamiento de una enfermedad en un sujeto que lo necesita. El metodo comprende el suministro al sujeto de una cantidad terapeuticamente efectiva de un compuesto que sea capaz de disminuir la actividad y/o nivel de un peptido antimicrobiano (PAM) y/o una molecula similar al PAM, tratando con esto la enfermedad en el sujeto que lo necesita.
MXPA05006359A 2002-12-19 2003-12-21 Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos. MXPA05006359A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL15355702A IL153557A0 (en) 2002-12-19 2002-12-19 Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases
IL15698003A IL156980A0 (en) 2003-07-17 2003-07-17 Antibodies and antagonists to antimicrobial peptides and proteins for the purpose of treating, inhibiting and preventing autoimmune, inflammatory and other diseases
PCT/IL2003/001094 WO2004056307A2 (en) 2002-12-19 2003-12-21 Disease treatment via antimicrobial peptide inhibitors

Publications (1)

Publication Number Publication Date
MXPA05006359A true MXPA05006359A (es) 2006-02-08

Family

ID=32684044

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006359A MXPA05006359A (es) 2002-12-19 2003-12-21 Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos.

Country Status (10)

Country Link
US (2) US20060115480A1 (es)
EP (1) EP1572101A4 (es)
JP (1) JP2006514106A (es)
KR (1) KR20050089827A (es)
AU (1) AU2003288507A1 (es)
CA (1) CA2508273A1 (es)
IL (1) IL169161A (es)
MX (1) MXPA05006359A (es)
NZ (1) NZ540506A (es)
WO (1) WO2004056307A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0300207D0 (sv) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
WO2004098536A2 (en) * 2003-03-06 2004-11-18 The Regents Of The University Of California Anti-viral activity of cathelicidin peptides
US7741275B2 (en) 2004-12-22 2010-06-22 Lipopeptide Ab Agents and use thereof
US9044438B2 (en) 2005-06-17 2015-06-02 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
US7528107B2 (en) * 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
GB0608797D0 (en) * 2006-05-04 2006-06-14 Lipopeptide Ab Novel agents and the use thereof
GB0608806D0 (en) * 2006-05-04 2006-06-14 Lipopeptide Ab Combination therapy product and uses thereof
WO2008073174A2 (en) * 2006-09-08 2008-06-19 The Regents Of The University Of California Antimicrobial therapy
US20090318534A1 (en) * 2006-09-27 2009-12-24 The Regents Of The University Of California Methods and compositions for the treatment of skin diseases and disorders
US20110033448A1 (en) * 2006-12-15 2011-02-10 Michel Gilliet Inhibitors of LL-37 Mediated Immune Reactivity to Self Nucleic Acids
US20100166708A1 (en) * 2007-02-20 2010-07-01 The Regents Of The University Of California Antimicrobial and anti-inflammatory therapies and compositions
AU2008277257B2 (en) * 2007-07-15 2014-03-06 Hillman, Yitzchak Mr Disease treatment via antimicrobial peptides or their inhibitors
PT2178549T (pt) * 2007-07-26 2016-12-20 Revance Therapeutics Inc Péptido antimicrobiano e suas composições
EP2242854A4 (en) * 2008-01-15 2012-08-15 Quark Pharmaceuticals Inc COMPOUNDS AND USES THEREOF
EP2320928B1 (en) * 2008-07-18 2012-11-07 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with human beta defensins
NZ593653A (en) * 2008-07-18 2012-09-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins
MX2011000569A (es) * 2008-07-18 2011-02-23 Novozymes Adenium Biotech As Tratamiento de enfermedades inflamatorias con beta-defensinas de mamifero.
CA2758967A1 (en) 2009-04-16 2010-10-21 Forsyth Dental Infirmary For Children New methods of making an antibody and compositions thereof
US20120214705A1 (en) * 2009-09-28 2012-08-23 The Regents Of The University Of California Office of Technology, Beta-defensin 2 genetic variation predicts h. pylori susceptibility
US20160289679A1 (en) * 2010-11-12 2016-10-06 Biotex, Inc. Nucleic acid ligands to ll37
KR20190110156A (ko) * 2011-06-02 2019-09-27 더 리전츠 오브 더 유니버시티 오브 캘리포니아 세타-디펜신들로 염증성 프로테아제들의 차단
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
AU2013359040A1 (en) 2012-12-14 2015-07-02 The Procter & Gamble Company Fragrance materials
US9801848B2 (en) * 2013-03-13 2017-10-31 The Regents Of The University Of California Prevention of rosacea inflammation
MX2015012298A (es) * 2013-03-15 2015-12-16 Procter & Gamble Un metodo no invasivo para medir peptidos antimicrobianos de la piel como una medicion objetica de proteccion natural de los microbios.
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
CN104910265B (zh) * 2015-06-17 2018-03-30 贵州师范大学 一种合江棘蛙抗菌肽及其编码序列的基因与应用
DK3389620T3 (da) 2015-12-15 2022-12-19 Medicell Tech Llc Stamcellestimulerende sammensætninger og fremgangsmåder til behandling af melasma
WO2019018445A1 (en) * 2017-07-17 2019-01-24 Maxwell Biosciences, Inc. POLYTHERAPY MODULATING THE MODULATION OF CATHELICIDINE GENE EXPRESSION FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISEASES
US20200361861A1 (en) * 2017-08-17 2020-11-19 Cornell University Oligothioetheramides (oligoteas) as anti-microbial and anti-bacterial agents
AU2018371948A1 (en) * 2017-11-24 2020-06-11 Defensin Therapeutics Aps Prevention and treatment of graft-versus-host-disease with defensins
US11134870B2 (en) * 2018-05-08 2021-10-05 Envivo Diagnostics, LLC In vivo sensor
EP4319849A1 (en) * 2021-04-08 2024-02-14 The Children's Hospital of Philadelphia Antimicrobial eluting airway devices

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5743194A (en) * 1992-12-03 1994-06-22 Magainin Pharmaceuticals, Inc. Treatment of dermatological malignancies with biologically active peptides
EP0702554A1 (en) * 1993-06-07 1996-03-27 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Use of an mhc class i suppressor drug for the treatment of autoimmune diseases and transplantation rejection
ATE193203T1 (de) * 1993-10-25 2000-06-15 Liposome Co Inc Liposomale defensine
EP0960191A4 (en) * 1996-08-22 2003-07-23 Univ Pennsylvania COMPOSITIONS AND METHODS FOR THE USE OF DEFENSIN
FR2767832B1 (fr) * 1997-08-29 2001-08-10 Genset Sa Polypeptide defensine humaine def-x, adn genomique et adnc, composition les contenant et applications au diagnostic et au traitement therapeutique
JP2001517422A (ja) * 1997-09-25 2001-10-09 アカデミス・ジーケンハイス・ベイ・デ・ウニフェルジテイト・ファン・アムステルダム 単離したおよび組換えによる抗菌ペプチドトロンボシジン−１（ｔｃ−１）およびトロンボシジン−２（ｔｃ−２）またはその変異体
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
US6706759B1 (en) * 1998-09-08 2004-03-16 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
EP1143954B1 (en) * 1998-12-01 2004-08-11 University of Kentucky Research Foundation Use of nicotinic acid derivatives for the treatment of dna damage in skin cells
US6335318B1 (en) * 1999-05-10 2002-01-01 The Regents Of The University Of California Antimicrobial theta defensins and methods of using same
EP1299541B1 (de) * 2000-07-11 2007-09-12 IPF Pharmaceuticals GmbH Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen
US20020072495A1 (en) * 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant
GB0300718D0 (en) * 2003-01-13 2003-02-12 Ares Trading Sa Proteins
WO2004098536A2 (en) * 2003-03-06 2004-11-18 The Regents Of The University Of California Anti-viral activity of cathelicidin peptides
US7846017B2 (en) * 2004-07-06 2010-12-07 Igt Methods and apparatus for facilitating remote viewing of gaming outcomes
US8202835B2 (en) * 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors

Also Published As

Publication number Publication date
IL169161A (en) 2012-07-31
EP1572101A4 (en) 2008-04-09
IL169161A0 (en) 2007-07-04
AU2003288507A1 (en) 2004-07-14
EP1572101A2 (en) 2005-09-14
WO2004056307A3 (en) 2005-09-15
US20100297150A1 (en) 2010-11-25
NZ540506A (en) 2008-09-26
CA2508273A1 (en) 2004-07-08
WO2004056307A2 (en) 2004-07-08
US20060115480A1 (en) 2006-06-01
JP2006514106A (ja) 2006-04-27
KR20050089827A (ko) 2005-09-08

Similar Documents

Publication Publication Date Title
MXPA05006359A (es) Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos.
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
GB0225474D0 (en) Therapeutic agents
MY151032A (en) Treatment of tnf? related disorders
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
WO2004006906A3 (en) Methods for the treatment of neoplasms
WO2000040235A3 (en) Treatment of asthma with mek inhibitors
WO2003106629A3 (en) TREATMENT OF VITAMIN D INFLUENCED DISEASES
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
EP1572101A3 (en) Disease treatment via antimicrobial peptide inhibitors
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
GB0222514D0 (en) Organic compounds
SE0104248D0 (sv) Method of treatment
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
MY136449A (en) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide for the treatment of cancer
SE0100684D0 (sv) New subject-matter
MXPA05006408A (es) Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos.

Legal Events

Date Code Title Description
FG Grant or registration